Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2026 · third_quarter · Q3
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2026 · third_quarter · Q3
Source: Senate LDA
| HIGHPOINT GLOBAL, LLC | 1 | 2017 |
340B, MFN and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2026 · second_quarter · 2A
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2026 · second_quarter · Q2
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2026 · second_quarter · Q2
340B, MFN and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2026 · first_quarter · Q1
340B, MFN and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2026 · first_quarter · Q1
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2025 · fourth_quarter · Q4
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2025 · fourth_quarter · Q4
340B and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2025 · third_quarter · Q3
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2025 · third_quarter · Q3
340B and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2025 · second_quarter · Q2
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2025 · second_quarter · Q2
340B and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2025 · first_quarter · Q1
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2025 · first_quarter · Q1
340B and drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2024 · fourth_quarter · Q4
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2024 · fourth_quarter · Q4
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2024 · third_quarter · Q3
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2024 · third_quarter · Q3
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2024 · second_quarter · Q2
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2024 · second_quarter · Q2
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2024 · first_quarter · Q1
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2024 · first_quarter · Q1
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2023 · second_quarter · RA
Various health care reform, biopharmaceutical and life science issues.
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2023 · fourth_quarter · Q4
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2023 · fourth_quarter · Q4
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2023 · third_quarter · Q3
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2023 · third_quarter · Q3
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2023 · second_quarter · Q2
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2023 · second_quarter · Q2
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2023 · first_quarter · Q1
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2023 · first_quarter · Q1
Drug pricing and 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA via BOSE PUBLIC AFFAIRS GROUP
2023 · first_quarter · RR
Various health care reform, biopharmaceutical and life science issues.
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2022 · fourth_quarter · Q4
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2022 · fourth_quarter · Q4
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2022 · fourth_quarter · Q4
Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2022 · third_quarter · Q3
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2022 · third_quarter · Q3
Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2022 · second_quarter · Q2
Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2022 · second_quarter · Q2
Issues related to organ transplant and organ donation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2022 · first_quarter · Q1
COVID R&D, Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2022 · first_quarter · Q1
COVID-19 state-level public health response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2021 · fourth_quarter · Q4
COVID R&D, Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2021 · fourth_quarter · Q4
COVID-19 state-level public health response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2021 · third_quarter · Q3
COVID R&D, Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2021 · third_quarter · Q3
COVID-19 state-level public health response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2021 · third_quarter · RR
policies impacting biopharmaceutical industry
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2021 · second_quarter · Q2
COVID-19 state-level public health response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2021 · second_quarter · Q2
COVID R&D, Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2021 · first_quarter · Q1
COVID-19 state-level public health response.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2021 · first_quarter · Q1
COVID R&D, Medicare Part D, drug pricing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2020 · fourth_quarter · Q4
donor transplant policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2020 · fourth_quarter · Q4
Drug Pricing, COVID R&D, Medicare Part B and D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2020 · third_quarter · Q3
donor transplant policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2020 · third_quarter · Q3
Drug Pricing, COVID R&D, Medicare Part B and D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2020 · second_quarter · Q2
donor transplant policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2020 · second_quarter · Q2
Drug Pricing, Medicare Part B and D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2020 · first_quarter · Q1
Importation, Drug Pricing, Medicare Part B and D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2020 · first_quarter · Q1
donor transplant policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDIANA DONOR NETWORK via BOSE PUBLIC AFFAIRS GROUP
2020 · first_quarter · RA
Issues related to organ transplant and organ donation
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2019 · fourth_quarter · Q4
Importation, Drug Pricing, Medicare Part B and D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2019 · third_quarter · Q3
Importation, IPI, Medicare Part B and Part D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2019 · second_quarter · Q2
Importation, Medicare Part B and Part D issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2019 · first_quarter · Q1
Importation, Medicare Part B and Part D issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2018 · fourth_quarter · Q4
Medicare Part B and Part D issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2018 · third_quarter · Q3
Medicare Part B and Part D issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2018 · second_quarter · Q2
Medicare Part B and Part D issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2018 · first_quarter · Q1
Healthcare, bio-pharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PILLSBURY WINTHROP SHAW PITTMAN LLP ON BEHALF OF EURONET WORLDWIDE, INC. via BOSE PUBLIC AFFAIRS GROUP
2017 · fourth_quarter · 4T
Education regarding potential transactions in money transfer business sector
Education regarding potential transactions in money transfer business sector
Education regarding potential transactions in money transfer business sector.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Vice President of the U.S.
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2017 · fourth_quarter · Q4
Healthcare, bio-pharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PILLSBURY WINTHROP SHAW PITTMAN LLP ON BEHALF OF EURONET WORLDWIDE, INC. via BOSE PUBLIC AFFAIRS GROUP
2017 · fourth_quarter · Q4
Education regarding potential transactions in money transfer business sector
Education regarding potential transactions in money transfer business sector
Education regarding potential transactions in money transfer business sector.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, Vice President of the U.S.
PILLSBURY WINTHROP SHAW PITTMAN LLP ON BEHALF OF EURONET WORLDWIDE, INC. via BOSE PUBLIC AFFAIRS GROUP
2017 · third_quarter · Q3
Education regarding potential transactions in money transfer business sector
Education regarding potential transactions in money transfer business sector
Education regarding potential transactions in money transfer business sector.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2017 · third_quarter · Q3
Healthcare, bio-pharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PILLSBURY WINTHROP SHAW PITTMAN LLP ON BEHALF OF EURONET WORLDWIDE, INC. via BOSE PUBLIC AFFAIRS GROUP
2017 · second_quarter · Q2
Education regarding potential transactions in money transfer business sector
Education regarding potential transactions in money transfer business sector.
Education regarding potential transactions in money transfer business sector
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2017 · second_quarter · Q2
Healthcare, bio-pharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HIGHPOINT GLOBAL, LLC via BOSE PUBLIC AFFAIRS GROUP
2017 · second_quarter · RR
Policy issues affecting citizens experience with government as well as related contracting opportunities for consulting and IT services
Policy issues affecting citizens experience with government as well as related contracting opportunities for consulting and IT services
Policy issues affecting citizens experience with government as well as related contracting opportunities for consulting and IT services
PILLSBURY WINTHROP SHAW PITTMAN LLP ON BEHALF OF EURONET WORLDWIDE, INC. via BOSE PUBLIC AFFAIRS GROUP
2017 · second_quarter · RR
National security issues related to financial transactions
National security issues related to financial transactions
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2017 · first_quarter · Q1
Healthcare, bio-pharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CROWN HILL MANANGEMENT LLC via BOSE PUBLIC AFFAIRS GROUP
2017 · first_quarter · RR
Regulatory policy related to proposed expansion of National Veterans Cemetery
Regulatory policy related to proposed expansion of National Veterans Cemetery
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2016 · fourth_quarter · Q4
Health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2016 · third_quarter · Q3
Health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2016 · second_quarter · Q2
Health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2016 · first_quarter · 1A
Health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2016 · first_quarter · Q1
Health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2015 · fourth_quarter · Q4
Health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2015 · third_quarter · Q3
Health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2015 · second_quarter · Q2
health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2015 · first_quarter · Q1
health care, biopharmaceutical and life sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2014 · fourth_quarter · Q4
Health Care, Biopharmaceutical and Life Sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2014 · third_quarter · Q3
Health Care, Biopharmaceutical and Life Sciences
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2014 · second_quarter · Q2
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2014 · first_quarter · Q1
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2013 · fourth_quarter · Q4
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2013 · third_quarter · Q3
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2013 · second_quarter · Q2
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2013 · second_quarter · Q2
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2013 · first_quarter · Q1
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2012 · fourth_quarter · Q4
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2012 · third_quarter · Q3
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA, ON BEHALF OF WE WORK FOR HEALTH via BOSE PUBLIC AFFAIRS GROUP
2012 · second_quarter · Q2
Health Care, Biopharmaceutical and Life Science Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE